

The listing of claims will replace all prior versions, and listings, of claims in the application. Please amend claim 1 as follows:

Listing of Claims:

Claim 1 (currently amended): A betacellulin mutein or a salt thereof ~~comprising~~
consisting of the amino acid sequence represented by SEQ ID NO: 38.

Claim 2 (previously amended): A betacellulin mutein or salt thereof according to Claim 1, wherein the ratio of the pancreatic β cell differentiation promoting activity to the epithelial cell growth promoting activity is at least twice relative to that of betacellulin.

Claims 3-11 (cancelled).

Claim ~~12~~³ (original): A method for manufacturing a betacellulin mutein or salt thereof according to Claim 1, characterized by culturing the transformants which have been transformed with recombinant vectors containing DNA encoding the betacellulin mutein according to Claim 1 to produce said betacellulin mutein.

Claim ~~13~~⁷ (original): A pharmaceutical composition comprising a betacellulin mutein or salt thereof according to Claim 1.

Claim 14 (cancelled).

Claim ~~15~~¹⁵ (previously added): A method for treatment for diabetes, characterized in that a betacellulin mutein or salt thereof according to Claim 1 is administered to mammals.

In re T. Ito, et al.
U.S.S.N. 09/857,815
Page 3 of 5

Claim 1⁶ (previously added): The betacellulin mutein or a salt thereof according to claim 1,
wherein the mutein has the pancreatic β cell differentiation promoting activity and the reduced
epithelial cell growth promoting activity.